Tekonivelsairaala Coxa Sites > Coxapro > Clinical Library > Tervetuloa Clinical Libraryyn > Long-Term Outcomes for Cementless Anatomic Femoral Components, Compared by Area of Porous Coating, in Patients Younger Than 50 Years Treated for Hip Dysplasia
The Journal of Arthroplasty, ISSN: 0883-5403, Vol: 36, Issue: 8, Page: 2864-2870
Hip
Link to article
Long-Term Outcomes for Cementless Anatomic Femoral Components, Compared by Area of Porous Coating, in Patients Younger Than 50 Years Treated for Hip Dysplasia
Kaneuji, Ayumi; Takahashi, Eiji; Fukui, Makoto; Ichiseki, Toru; Fukui, Kiyokazu; Kawahara, NorioHip
Background
We investigated whether the proximal circumferential porous coating of cementless stems would make implant survival of >20 years possible in young patients.
Methods
Data for patients younger than 50 years with hip dysplasia who had an anatomic stem implanted with a proximal porous coating with hydroxyapatite/tricalcium phosphate were reviewed. Noncircumferential porous (non-C-type) stems were used in 17 hips (13 cases), and circumferential porous (C-type) stems were used in 87 hips (68 cases). Acetabular components with conventional polyethylene were used for all hips. The mean ages at surgery for patients with non-C-type stems and those with C-type stems were 43.3 and 44.7 years, respectively. Stems that had not loosened were retained at the time of acetabular revision. The average duration of follow-up for patients with non-C-type stems was 26.9 years and was 22.3 years for those with C-type stems.
Results
Mean survival rates as determined by the Kaplan-Meier method were 74.9% at 20 years and 59.9% at 25 years for non-C-type stems and were 100% at 20 years and 94.0% at 25 years for C-type stems. The survivorship for C-type stems was significantly higher than that for non-C-type stems (P < .01). Focal osteolysis in the shoulder of 37 hips with C-type stems suppressed the spread of osteolysis to the distal femur.
Conclusion
Anatomic femoral stems with a circumferential porous coating provide excellent durability in patients with hip dysplasia who are 50 years of age or younger.
Level of Evidence
Therapeutic Level IV.
Link to article